HC Wainwright Issues Pessimistic Outlook for NAMS Earnings

Key Points

• HC Wainwright lowered its NewAmsterdam Pharma Q3 2026 EPS estimate to a loss of $0.62 per share from $0.58, forecasting a $0.28 loss in Q4 and a $1.82 full-year 2026 loss.
• NewAmsterdam Pharma reported a Q2 loss of $0.52 per share, missing consensus by $0.04, although quarterly revenue of $3.70 million exceeded the $2.83 million estimate.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $49.33 versus the stock’s recent $27.96 price; institutional investors own nearly 90% of shares.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - HC Wainwright lowered their Q3 2026 EPS estimates for NewAmsterdam Pharma in a report issued on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now expects that the company will post earnings per share of ($0.62) for the quarter, down from their prior estimate of ($0.58). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma's Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.82) EPS.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The business had revenue of $3.70 million during the quarter, compared to the consensus estimate of $2.83 million.

A number of other equities analysts have also commented on the company. Jefferies Financial Group restated a "buy" rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Royal Bank Of Canada cut their target price on NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating for the company in a research report on Thursday. Weiss Ratings reissued a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. BMO Capital Markets began coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an "outperform" rating and a $58.00 price target on the stock. Finally, Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma presently has an average rating of "Moderate Buy" and an average target price of $49.33.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS opened at $27.96 on Monday. The company has a market cap of $3.27 billion, a price-to-earnings ratio of -12.94 and a beta of 0.10. The company has a 50 day moving average of $31.37 and a 200-day moving average of $32.51. NewAmsterdam Pharma has a 1-year low of $23.05 and a 1-year high of $42.21.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors have recently modified their holdings of the business. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 1.4% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company's stock valued at $594,388,000 after acquiring an additional 241,818 shares during the last quarter. Capital World Investors lifted its holdings in shares of NewAmsterdam Pharma by 1.6% in the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company's stock worth $350,239,000 after acquiring an additional 161,289 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company's stock valued at $114,332,000 after purchasing an additional 697,129 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company's stock valued at $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Finally, Polar Capital Holdings Plc grew its holdings in shares of NewAmsterdam Pharma by 15.6% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company's stock valued at $82,807,000 after purchasing an additional 393,855 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the firm's stock in a transaction on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the sale, the chief accounting officer owned 24,353 shares of the company's stock, valued at approximately $738,870.02. This trade represents a 81.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 210,000 shares of company stock worth $6,713,550 in the last three months. 12.74% of the stock is owned by corporate insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source